+Equity
Financing & development infrastructure for biomanufacturing
Job no longer available
Financing & development infrastructure for biomanufacturing
21-100 employees
Job no longer available
+Equity
21-100 employees
To build production capacity for synthetic biology companies and create a new asset class for investors to enable fermentation at scale.
As an environmentally friendly alternative to traditional farming, biomanufacturing of food proteins is a key part of humanity's future. But although the science is ready, the infrastructure is not, and the cost of production at scale is preventing revolutionary and essential products from reaching the supply chain.
Synonym exists to support biomanufacturing firms in building production facilities that will allow their products to compete with and outperform traditional sources of protein. With global food production responsible for about a third of carbon emissions (the majority of which is in the production of proteins), this work is vital.
Synonym aims to develop standardized designs for biofermentation facilities that its customers will be able to use instead of making their own at vast expense. This proposal has seen the company raise considerable funds that have supported its development so far. It has also announced a 32,000L+ fermentation scale-up facility in Illinois, in partnership with Primient, will be coming in early 2026.
Kirsty
Company Specialist at Welcome to the Jungle
Few candidates hear
back within 2 weeks
Aug 2024
$1.9m
GRANT
Oct 2022
$6.3m
SEED
Lenox Hill, New York, NY
Edward Shenderovich
(Co-Founder & CEO)Before co-founding Synonym, founded Essential Capital, Knotel and Merchantry. Was Head of Strategic Development at SUP Media and CEO of Quantum Art.
Joshua Lachte
(Co-Founder & CBO)Previously Vice President at ASAPP and Director of Operations with Greenmantle. Before that, they were a Founding Associate at Locus Analytics.
Share this job
View 1 more job at Synonym Biotechnologies